Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022
– IONIS-FB-L Rx achieved a 44% mean reduction in proteinuria in patients treated for 6 months – Roche to advance IONIS-FB-L Rx int...
